RT Journal Article
SR Electronic
T1 Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP 276
OP 277
DO 10.1136/thx.2004.035519
VO 62
IS 3
A1 Cornelis K van der Ent
A1 Hans Hoekstra
A1 Ger T Rijkers
YR 2007
UL http://thorax.bmj.com/content/62/3/276.1.abstract
AB Allergic bronchopulmonary aspergillosis (ABPA) can cause severe worsening of the respiratory condition in patients with cystic fibrosis. Treatment can result in steroid dependency and serious adverse events. A dramatic and rapid improvement of respiratory symptoms and lung function after a single dose of anti-IgE antibody (omalizumab) in a 12-year-old girl with cystic fibrosis and ABPA is described. This is the first report of this experimental treatment. It suggests an important role for IgE in the pathogenesis of ABPA and offers new therapeutic possibilities.